Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Interventions: Acoramidis, Placebo oral tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 40
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 31 more

Conditions: Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions: Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%; Drug
Lead sponsor: Waihong Chung; Other
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions: Fluzone High Dose Vaccine, Standard of care/Placebo; Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prematurity, Neurodevelopmental Disorder, Carnitine Deficiency
Interventions: L-carnitine, 5% Dextrose; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 1 Day to 3 Days
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: COPD Exacerbation Acute
Interventions: Trimethoprim Sulfamethoxazole, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 40 Years to 89 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder
Interventions: THC-dominant cannabis, CBD-dominant cannabis, Cannabis placebo, Alcohol, Alcohol placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hypertriglyceridemia
Interventions: Diazoxide choline, Placebo; Drug
Lead sponsor: Essentialis, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Miami Gardens, Florida + 8 more

Conditions: Hemodialysis
Interventions: Sacubitril-valsartan, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Critically Ill, Acute Kidney Injury
Interventions: Calcifediol, Calcitriol, Placebos; Drug
Lead sponsor: David Leaf; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Fecal Microbiota Transplant (FMT), Placebo; Biological
Lead sponsor: Stacy A. Kahn; Other
Eligibility: 5 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Pioglitazone; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Common Cold
Interventions: Echinacea, Blinded placebo; Dietary Supplement · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 12 Years and older
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alzheimer Disease
Interventions: 18F-MK-6240, 11C-PIB; Drug
Lead sponsor: José A. Luchsinger; Other
Eligibility: 60 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Drinking, Drinking Behavior, Physiological Effects of Drugs, Central Nervous System Depression
Interventions: Ethanol, Placebo; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 35 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hip Fractures, Anesthesia, Spinal, Anesthesia, General, Neuromuscular Blockade
Interventions: Rocuronium, Sugammadex, Normal saline; Drug
Lead sponsor: Loyola University; Other
Eligibility: 55 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Urinary Incontinence, Parkinson's Disease
Interventions: Solifenacin Succinate (VESIcare), Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 30 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Blood Loss, Surgical
Interventions: Tranexamic acid (TXA), Placebo Normal Saline (NS); Drug
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cardiac Surgical Procedures
Interventions: cyclosporine, saline solution; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Intracranial Hemorrhages
Interventions: Vitamin E, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 4 Hours
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 12 more

Conditions: Bone Metastases, Lymphoma, Multiple Myeloma, Opioid Use, Pain
Interventions: Ketorolac, Normal saline, Acetaminophen, Oxycodone Acetaminophen, Morphine, Hydrocodone/Acetaminophen, Oxycodone; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity
Interventions: Oral Alcohol challenge test Alcohol visit first, Oral Alcohol challenge test Placebo visit first, Intravenous Alcohol Challenge Test (Clamp), Intravenous Alcohol Self-administration Test; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years to 64 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Norovirus Infections
Interventions: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo; Drug
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Long Beach, California • Lenexa, Kansas • Saint Paul, Minnesota

Conditions: Fibroid Uterus, Abnormal Uterine Bleeding, Myoma;Uterus
Interventions: Tranexamic Acid, Placebos; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Chronic Kidney Diseases
Interventions: Ferric Citrate, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Years to 18 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 14 more

Search by objective public record fields.

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants

Treatment of Pneumocystis in COPD (the TOPIC Study)

Cannabis' Impact on Alcohol Consumption

Diazoxide Choline in Hypertriglyceridemia

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)

Brain Imaging in the Diabetes Prevention Program Outcomes Study

Behavior Brain Responses

GA/Spinal vs. GA/Spinal/NMB for Operative Repair of Hip Fracture

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

Tranexamic Acid for Total Knee Arthroscopy

Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery

Vitamin E for Extremely Preterm Infants

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Alcohol and Bariatric Surgery

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies

Ferric Citrate and Chronic Kidney Disease in Children